Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
暂无分享,去创建一个
A. Unterberg | A. Bartsch | A. von Deimling | W. Brück | D. Capper | B. Leuchs | J. Rommelaere | J. Neumann | K. Geletneky | J. Fry | V. Daniel | J. Hüsing | M. Dahm | A. Angelova | K. Jochims | Rauf Bhat | I. Kiprianova | O. Krebs | B. Huber | Jacek Hajda | T. Schöning | Veronika Frehtman | A. Just | Birgit Beelte | Mandy Roscher | Stephanie Löbhard | E. Terletskaia‐Ladwig | R. Bhat
[1] T. Mikkelsen,et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma , 2016, Science Translational Medicine.
[2] A. Melcher,et al. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. , 2016, Neuro-oncology.
[3] B. Leuchs,et al. Standardized large-scale H-1PV production process with efficient quality and quantity monitoring. , 2016, Journal of virological methods.
[4] J. Markert,et al. To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses , 2016, Viruses.
[5] G. Reifenberger,et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. , 2015, Neuro-oncology.
[6] J. Rommelaere,et al. Double-faceted mechanism of parvoviral oncosuppression. , 2015, Current opinion in virology.
[7] B. Leuchs,et al. Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats. , 2015, Comparative medicine.
[8] B. Leuchs,et al. Pathology, organ distribution, and immune response after single and repeated intravenous injection of rats with clinical-grade parvovirus H1. , 2015, Comparative medicine.
[9] P. Tattersall,et al. Parvoviruses: Small Does Not Mean Simple. , 2014, Annual review of virology.
[10] H. Urbach,et al. O10.04THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS: FINAL SURVIVAL RESULTS AND QUALITY OF LIFE , 2014 .
[11] C. Breitbach,et al. Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.
[12] E. Chiocca,et al. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] R. Weichselbaum,et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[14] R. Cattaneo,et al. New viruses for cancer therapy: meeting clinical needs , 2013, Nature Reviews Microbiology.
[15] Christina Appin,et al. Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class , 2013, Clinical Cancer Research.
[16] Johannes E. Schindelin,et al. Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.
[17] Kevin W Eliceiri,et al. NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.
[18] A. Marchini,et al. Molecular Pathways: Rodent Parvoviruses—Mechanisms of Oncolysis and Prospects for Clinical Cancer Treatment , 2012, Clinical Cancer Research.
[19] Y. De Launoit,et al. Activation of a Helper and Not Regulatory Human CD4+ T Cell Response by Oncolytic H-1 Parvovirus , 2012, PloS one.
[20] A. Ernst,et al. Microglia isolated from patients with glioma gain antitumor activities on poly (I:C) stimulation. , 2012, Neuro-oncology.
[21] M. von Knebel Doeberitz,et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol , 2012, BMC Cancer.
[22] Susan M. Chang,et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? , 2011, Neuro-oncology.
[23] D. Mouginot,et al. Combined fluorescent in situ hybridization and immunofluorescence: Limiting factors and a substitution strategy for slide-mounted tissue sections , 2011, Journal of Neuroscience Methods.
[24] T. Giese,et al. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent , 2010, Cancer biology & therapy.
[25] O. Witt,et al. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells , 2010, International journal of cancer.
[26] C. Sommer,et al. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. , 2010, Neuro-oncology.
[27] J. Rommelaere,et al. Oncolytic parvoviruses as cancer therapeutics. , 2010, Cytokine & growth factor reviews.
[28] B. Yoo,et al. Induction of glioma apoptosis by microglia-secreted molecules: The role of nitric oxide and cathepsin B. , 2009, Biochimica et biophysica acta.
[29] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[30] B. Thompson,et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[31] R. Ortíz-López,et al. Oncolytic virotherapy. , 2008, Annals of hepatology.
[32] J. Rommelaere,et al. Cytosolic Activation of Cathepsins Mediates Parvovirus H-1-Induced Killing of Cisplatin and TRAIL-Resistant Glioma Cells , 2007, Journal of Virology.
[33] J. Buckner,et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. , 2007, Neuro-oncology.
[34] David J. Yang,et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. , 2006, Neuro-oncology.
[35] J. Olson,et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[36] S. Brown,et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival , 2004, Gene Therapy.
[37] A. Silahtaroglu,et al. FISHing with locked nucleic acids (LNA): evaluation of different LNA/DNA mixmers. , 2003, Molecular and cellular probes.
[38] J. Pocock,et al. Microglial secreted cathepsin B induces neuronal apoptosis , 2001, Journal of neurochemistry.
[39] R. Martuza,et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.
[40] A. Maclean,et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma , 2000, Gene Therapy.
[41] P. Tattersall,et al. Biochemical Activities of Minute Virus of Mice Nonstructural Protein NS1 Are Modulated In Vitro by the Phosphorylation State of the Polypeptide , 1998, Journal of Virology.
[42] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[44] P. Tattersall,et al. Reciprocal productive and restrictive virus-cell interactions of immunosuppressive and prototype strains of minute virus of mice , 1983, Journal of virology.
[45] J. Stamp,et al. Viral diseases , 1975, Nature.
[46] J. Sever,et al. Attempts to isolate H-1 virus from spontaneous human abortions: a negative report. , 1970, Teratology.
[47] A. Levin,et al. H-1 Virus Viremia in the Human.∗ , 1965, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.